NECTIN4 and cancer: In the period 2015–2021, cancer continued to be the main target, but there was increasing interest in discovering new ways and new targets, reflected, for example, by a new class of biological as a fragment of an antibody (Efgartigimod) [80], the first therapy targeting Nectin-4 (Enfortumab Vedotin) [55,56].